PCRXPacira BioSciences, Inc.
Is it growing?
Neither accelerating nor breaking down: operating margin widening (+18.6 points), but earnings down −113% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +8% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 2.7% now against -15.9% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is PCRX growing?
Pacira BioSciences, Inc. has grown revenue 3.7% a year over three years and 8.2% a year over five, with earnings per share compounding at −22%.
Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +8.2%
Revenue growth, 5-year rate · +3.7% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −22%
Earnings per share, 3-year rate · revenue +3.7% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $542M
- Revenue FY2022
- $667M
- Revenue FY2023
- $675M
- Revenue FY2024
- $701M
- Revenue FY2025
- $726M
Annual income statements as filed with the SEC.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore